Previous Article | Next Article 
Infection and Immunity, January 2001, p. 360-366, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.360-366.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Biochemical and Biological Properties of Staphylococcal
Enterotoxin K
Paul M.
Orwin,1
Donald Y. M.
Leung,2
Heather
L.
Donahue,2
Richard P.
Novick,3 and
Patrick
M.
Schlievert1,*
Department of Microbiology, University of
Minnesota Medical School, Minneapolis, Minnesota,
554551; Department of Pediatrics,
National Jewish Medical and Research Center, Denver, Colorado
802062; and Skirball Institute of
Biomolecular Medicine, New York University Medical Center, New York,
New York 100163
Received 6 July 2000/Returned for modification 26 September
2000/Accepted 19 October 2000
 |
ABSTRACT |
Staphylococcus aureus is an important human pathogen
which is implicated in a wide variety of diseases. Major determinants of the virulence of this organism include extracellular virulence factors. Staphylococcal enterotoxins (SEs) are important causative agents in staphylococcal toxic shock syndrome and food poisoning. Our
study identified a novel enterotoxin, SEK, and examined its biochemical
and biological properties. SEK had a molecular weight of 26,000 and an
experimentally determined pI of between 7.0 and 7.5. SEK was secreted
by clinical isolates of S. aureus. We demonstrated that SEK
had many of the biological activities associated with the SEs,
including superantigenicity, pyrogenicity, the ability to enhance the
lethal effect of endotoxin, and lethality in a rabbit model when
administered by subcutaneous miniosmotic pump. Recombinant SEK was
shown to stimulate human CD4+ and CD8+ T cells
in a V
-specific manner; T-cells bearing V
5.1, 5.2, and 6.7 were
significantly stimulated to proliferate.
 |
INTRODUCTION |
Staphylococcus aureus is
an important pathogen due to a combination of toxin-mediated virulence,
invasiveness, and antibiotic resistance (5, 7, 9, 12, 14, 31,
35). The organism is a significant cause of nosocomial
infections, as well as community-acquired disease. The spectrum of
staphylococcal infection ranges from pimples and furuncles to toxic
shock syndrome (TSS) and sepsis (24, 26, 35).
The virulence factors secreted by S. aureus are major
determinants of both disease causation and severity during the course of infection. These factors include several hemolysins (
,
,
,
and
), leukocidin, exfoliative toxins A and B, and the large family
of pyrogenic toxin superantigens (PTSAgs) (reviewed in references
5, 11, and 20). The latter toxins include toxic shock
syndrome toxin 1 (TSST-1) and the staphylococcal enterotoxins (SEs) A
to J, excluding F (11). All of the staphylococcal PTSAgs are encoded on variable genetic elements, with TSST-1 and enterotoxins B and C, among others, being present on pathogenicity islands (SaPIs)
(29).
Numerous studies have shown that PTSAgs are important determinants for
TSS (11) and food poisoning (reviewed in reference 2). Todd and coworkers were the first to recognize
S. aureus as the etiologic agent of TSS
(56). Subsequent work by Schlievert et al.
(51) and Bergdoll and colleagues (3)
identified TSST-1 as the major toxin associated with this illness,
whether menstrual or nonmenstrual associated; TSST-1 accounts for 75%
of all TSS cases. Later work by Schlievert and others established that
SEs, notably SEB and -C, were important causes of
nonmenstrual-associated TSS (3, 48). The SEs,
particularly SEA and -D, and, to a lesser extent, SEB and -C, are
also common causes of staphylococcal food poisoning (11,
54).
Crystallographic studies of the PTSAgs have shown that these
molecules share the same basic three-dimensional structure (11, 50). The toxins begin with a short N-terminal
helix that
leads into a
barrel structure, also known as the B domain or
oligonucleotide binding (OB). The OB fold is connected to a C-terminal
wall of
strands by a central diagonal
helix, forming
domain A. All PTSAgs have these features in common, but some differ in
that they have a small number of additional loops. The most
notable of these is a cystine loop structure present in the
SEs (15). This cystine loop is thought to be important for
emetic activity, based on studies of mutants (11, 15).
Recently, however, SEI has been identified, which lacks the cystine
loop structure; this toxin is both superantigenic and emetic,
although the emetic activity is significantly reduced
(34).
Overall, the PTSAgs share numerous biological activities, including
superantigenicity, pyrogenicity, the capacity to enhance endotoxin
shock, and lethality when administered in subcutaneous miniosmotic
pumps (11, 50). For superantigenicity (18, 30, 31), PTSAgs bind to the variable region of the
chain (V
) of certain T-cell receptors (TCRs). This mode of binding to the TCR is
much less specific than the typical TCR-peptide-major
histocompatibility complex (MHC) II trimolecular complex that is
required for T-cell activation. Depending on the V
specificity of
the PTSAg, up to 50% of the host T cells may be activated, resulting
in massive cytokine release, with concomitant induction of capillary
leak (hypotension) (8, 11, 30, 33). The other biological
activities, pyrogenicity, endotoxin enhancement, and lethality when
given in miniosmotic pumps, are also dependent on cytokine release
(11). Among PTSAgs, only SEs have emetic activity, and
this activity has been separated from superantigenicity (11,
15).
This study was undertaken to purify and characterize a new SE,
designated SEK, and to determine whether a functional PTSAg is encoded
by its gene. In this report, we demonstrate that recombinant SEK (rSEK)
functions as a superantigen and is lethal in rabbit models of TSS, and
the toxin is expressed by clinical isolates.
 |
MATERIALS AND METHODS |
Cloning and sequencing.
The gene sek was cloned
from S. aureus TSS isolate MN NJ. This isolate produces SEB
as well as SEK. PCR primers were chosen based on the sek
sequence of SaPI1 (29), as well as comparison with the
unfinished genome sequence of methicillin-resistant S. aureus strain COL, available online at the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). PCR primers including several hundred nucleotides at either end of the gene were
included in the original clone. The sequences of the sek primers were 5' GAATTACGTTGGCGAATC and 3'
AGGGTAGGCGGGC. The PCR product was electrophoresed in 1%
agarose, and the 1.4-kb band containing the entire sek gene
was cut out of the gel. The DNA was purified from the agarose by using
the Geneclean II kit (Bio101, La Jolla, Calif.) and cloned into the TA
vector pGEM T-easy (Promega, Madison, Wis.), resulting in the plasmid
pPMO001. The vector plasmid contains TT overhangs that allow for
cloning of PCR products directly without restriction digestion.
Subsequently, the gene was excised from this vector with
EcoRI, using restriction sites on either side of the
insertion site in the vector, and ligated with
EcoRI-digested plasmid vector pCE104 (44). The
resultant plasmid was transformed into Escherichia coli XL-1
Blue (Stratagene, La Jolla, Calif.), and a DNA insert with a
restriction fragment of the proper length was verified by plasmid
purification with the Qiagen Spin Miniprep kit (Qiagen, Valencia,
Calif.), digestion with EcoRI, and separation in 1% agarose
gels. This plasmid was referred to as pPMO002. The DNA sequence of
sek was determined by automated sequencing with fluorescent
labeled deoxynucleoside triphosphates (dNTPs) (Advanced Genetic
Analysis Center, St. Paul, Minn.). Further constructs were made with
this plasmid as a template. In order to examine the biochemical and
biological properties of SEK, a signal sequence deletion mutant was
cloned into pET28b by PCR amplification of the pCE104 (pPMO002)
sek insert, resulting in pPMO003. Restriction sites were
encoded in the primers for translation of the gene from the pET28b
ribosome binding site (RBS). The primer sequence were 5'
GGGGGATCCTTATATCGTTTCTTTATAAGAAATATCGAC and 3'
CCCCCATGGGCCAAGGTGATATAGGAATTGATAAT. Transformation of pPMO003
into E. coli XL-1 Blue (Stratagene) was followed by
purification of the plasmid and verification of the desired construct
by restriction digestion with NcoI and BamHI. Subsequent to verification, the plasmid was introduced into E. coli BL-21 DE3 for expression with the ptac
system. The deleted signal peptide of SEK was replaced with an
N-terminal methionine. In addition, for the purposes of expression in
pET28b, the N-terminal glutamine was replaced with glycine. The
N-terminal sequence of rSEK was MGGDIGIDNLR.
Expression and purification.
The pET28b clone containing
sek (pPMO003) in BL-21 DE3 was grown to early log phase in
Luria-Bertani medium supplemented with kanamycin (50 µg/ml) at 37°C
with shaking (approximately 100 rpm; Gyrotary Shaker; New Brunswick
Scientific, New Brunswick, N.J.) and then induced with 200 mM
isopropyl-
-D-thiogalactopyranoside (IPTG). At the same
time, 1-ml amounts of early-log-phase culture in 15% glycerol were
stored at
70°C for use in subsequent experiments. After growth
overnight under the same conditions, the cultures were treated with 4 volumes of absolute ethanol for 48 h to precipitate toxins. The
precipitated extracellular and released periplasmic proteins were
resuspended at a concentration 20 times that of the original culture
volume and examined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under reducing conditions (21). Proteins were stained with Coomassie blue R250. Induction of the expression system was ascertained by the presence of a prominent band
of the expected size of rSEK in the extract. Subsequent growth, expression, and purification of SEK were done through use of the stored
frozen aliquots of the original culture.
Large-scale production of rSEK was performed analogously to the above
protocol. Beef heart medium (1,200 ml in Feherenbach flasks),
containing 1% glucose-phosphate buffer (51) and 50 µg
of kanamycin per ml, was inoculated with 200 µl of the frozen expression clone. The culture was grown to early log phase and induced
with 200 mM IPTG as before. Proteins were precipitated in the presence
of 4 volumes of ethanol for 48 h, followed by decantation and
collection of the precipitate by centrifugation (500 × g, 10 min). Five liters of total culture volume was combined in a
single toxin preparation. The precipitate was air dried after centrifugation and then resuspended in 100 to 150 ml of pyrogen-free water. The resuspended precipitate was centrifuged at 10,000 × g for 30 min, and the concentrated supernatant was removed,
placed in molecular weight 12,000 to 14,000 exclusion dialysis tubing (Spectrum Laboratories, Inc., Miami, Fla.), and dialyzed overnight against 4 liters of distilled water. The dialyzed supernate was then
subjected to preparative isoelectric focusing. Successive gradients of
pH 3.5 to 10 and 6 to 8 were used to isolate highly pure rSEK. Final
purification of rSEK was accomplished with a gel filtration column
(Bio-Rad Laboratories, Hercules, Calif.) containing Sephadex G-75
(Sigma). Purity was verified by SDS-PAGE in which 10 µg gave a
homogeneous band of the appropriate molecular weight. The purified
protein concentration was assessed with the Bradford protein assay
(Bio-Rad), and protein was stored in the lyophilized state until used
in biological and biochemical assays. A standard curve for the Bradford
assay was developed by using purified TSST-1 diluted from 1 mg/ml as
determined by Ouchterlony double immunodiffusion (39).
Hyperimmune serum.
An American Dutch Belted rabbit
(Birchwood Farms, Grantsburg, Wis.) was immunized with 50 µg of
purified rSEK in phosphate-buffered saline (PBS; 0.005 M
NaPO4 [pH 7.2], 0.15 M NaCl) after being emulsified in
Freund's incomplete adjuvant. This mixture was injected subcutaneously
into the rabbit three times at 2-week intervals. One week after the
last injection, blood was drawn from the hyperimmunized animal. The
blood was allowed to clot overnight and then centrifuged (500 × g, 10 min) to separate the serum fraction. The
serum was stored at 4°C and preserved with a drop of liquified phenol.
Biochemical assays.
The size and homogeneity of purified
rSEK were determined by SDS-PAGE and Western immunoblotting
(4) with a rabbit polyclonal antiserum to rSEK used as the probe.
Superantigenicity assay.
Rabbit splenocytes were seeded into
the wells of a 96-well microtiter plate at a concentration of 2 × 105 cells per well. Serial 10-fold dilutions of rSEK or
TSST-1 were added to each well in quadruplicate, starting with 1 µg/well and with dilution to 10
8 µg/well. These
dilutions were compared to cells incubated in the presence of PBS
alone. The splenocytes were grown at 37°C for 3 days and pulsed with
1 µCi of [3H]thymidine overnight (51). The
cells were harvested the next day, and cell proliferation
(incorporation of 3H into DNA) was measured in a
scintillation counter (Beckman Instruments, Fullerton, Calif.).
Pyrogenicity and endotoxin enhancement.
American Dutch
Belted rabbits were injected with rSEK at doses of 4.5, 0.45, and 0.045 µg/kg of body weight per ml intravenously. Three rabbits were
injected with each dose. Each rabbit's temperature was measured with
rectal thermometers at 0 and 4 h. After 4 h, each rabbit was
injected intravenously with 10 µg of lipopolysaccharide (LPS) from
Salmonella enterica serovar typhimurium (1/50 of the 50%
lethal dose of endotoxin alone). The lethality of this toxin regimen
over a 48-h period was assessed (47, 52).
Miniosmotic pump lethality studies.
Six American Dutch
Belted rabbits had miniosmotic pumps, containing 200 µl (200 µg) of
either TSST-1 or rSEK, implanted subcutaneously on the left flank
(41). Lethality of the toxins was assessed over a period
of 15 days.
Expression of SEK by clinical isolates.
Clinical TSS
isolates (36) that tested positive for TSST-1, SEB, or SEC
were also evaluated for production of SEK. Crude supernatants (10 ml)
of these isolates were collected by centrifugation, and toxin was
precipitated with ethanol as described above. The precipitates were
resuspended at a 100× concentration in sterile pyrogen-free water.
Toxin production was detected by use of Ouchterlony double
immunodiffusion (39) and by Western immunoblotting
(4) with antibody raised against rSEK as the probe.
Flow cytometric analysis of T-cell repertoire.
Peripheral
blood mononuclear cells (PBMCs) obtained from three normal human donors
were isolated from heparinized venous blood by density gradient
sedimentation over Ficoll-Hypaque (Histopaque; Sigma Chemical Co.,
St. Louis, Mo.). Cells were then washed three times in Hanks balanced
salt solution (HBSS; Mediatech Cellgro, Herndon, Va.) and resuspended
in medium for cell culture. PBMCs (at 106 cells/ml) were
cultured in RPMI 1640 (Mediatech Cellgro) supplemented with 10%
heat-inactivated fetal calf serum (Gemini Bioproducts, Woodland,
Calif.), 20 mM HEPES buffer (Mediatech Cellgro), 100 U of penicillin
per ml (Mediatech Cellgro), 100 µg of streptomycin per ml (Mediatech
Cellgro), and 2 mM L-glutamine (Mediatech Cellgro). Cells
were cultured in the presence of either anti-CD3 (20 ng/ml) or SEK (100 ng/ml) for 3 days, washed, and allowed to grow for an additional day in
the presence of interleukin 2 (50 U/ml) before being washed and stained
for immunofluoresence analysis of the T-cell repertoire as previous
described (23, 25, 53). For flow cytometry studies, PBMCs
were washed in HBSS and resuspended at 10 × 106
cells/ml in a staining solution (PBS with 5% fetal calf serum [FCS;
Gemini Bioproducts], 1% immunoglobulin [Alpha Therapeutic Corp., Los
Angeles, Calif.], 0.02% sodium azide [Sigma]). Cells were stained
in 96-well, round-bottomed plates with a panel of biotinylated
monoclonal antibodies against human V
2, 3, 5.1, 5.2, 7, 8, 11, 12, 13.1, 13.2, 14, 16, 17, 20, 21.3, and 22 (Immunotech, Westbrook,
Maine); V
9 and 23 (Pharmingen, San Diego, Calif.); and V
6.7-fluorescein isothiocyanate (FITC) (Endogen, Woburn, Mass.) and then
incubated for 30 min at 37°C in the dark. After the incubation
period, cells were washed twice with washing buffer (PBS, 2% FCS
[Gemini Bioproducts], 0.02% sodium azide [Sigma]) by
centrifugation at 300 × g for 5 min at 4°C. Cell
pellets were resuspended in staining solution and incubated with
anti-CD3 allophycocyanin, anti-CD4 phycoerythrin (Becton
Dickinson, San Jose, Calif.), anti-CD8 (FITC) (Becton Dickinson),
and a streptavidin-peridinin-chlorophyll protein (PerCP)
conjugate (Becton Dickinson) for 30 min at 4°C. Stained cells were
again washed twice in washing buffer and once in 0.02% sodium azide
(Sigma) in PBS, by centrifugation at 300 × g for 5 min
at 4°C. Finally, the cells were fixed in 200 µl of 1% (vol/vol)
formaldehyde (Polysciences, Warrington, Pa.) in PBS. Analysis was
performed by four-color flow cytometry (FACSCalibur; Becton Dickinson)
as described previously (53). Methods of cytometer setup
and data acquisition have also been described previously (53). List mode multiparameter data files (each file with
forward scatter, side scatter, and 4 fluorescent parameters) were
analyzed with the Cellquest program (Becton Dickinson). Analysis of
activated populations was performed with the light scatter gate set on
the T-cell blast population. Negative control reagents were used to verify the staining specificity of experimental antibodies.
 |
RESULTS |
Sequence of sek.
sek was cloned and sequenced
from the clinical isolate MN NJ. The open reading frame encoded a
polypeptide 242 amino acids in length (Fig.
1). This polypeptide was nearly identical
to an open reading frame present in SaPI1 (29). The
reading frame presented here was named sek, and we suggest
renaming ent from SaPI1 to sek2. In the putative
regulatory region of sek, we identified a potential RBS as
well as possible
35 and
10 promoter sequences (Fig. 1). The two
putative SEK polypeptides (from MN NJ and RN 4282 containing SaPI1)
differed by two amino acids, one of which was in the likely signal
peptide. Using the online signal peptide prediction program SignalP
v.1.1 (Center for Biological Sequence Analysis;
http://www.cbs.dtu.dk/services/SignalP), we predicted the
N-terminal sequence of the secreted form of SEK to be QGDIGIGNLR. Amino acid homology to the other PTSAgs was also examined by
using the predicted mature SEK protein. We observed that SEK fit into a
subfamily of PTSAgs together with SEI and another recently identified enterotoxin (unpublished data), designated SEL (Fig.
2). These three relatively new toxins
(SEI, SEK, and SEL) comprised a new subfamily of SEs. These toxins were
distinct from the other subfamilies of SEs in that they lacked the
cystine loop hypothesized to be important in emetic activity. This
family was related to the SEA subgroup more closely than the SEB-SEC
subgroup, despite linkage on a pathogenicity island to the latter toxin
subfamily (Fig. 2). Some regions of the toxins retain significant
homology across all three toxin subfamilies (Fig.
3).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleotide and inferred amino acid sequences of
sek and SEK, respectively, cloned from staphylococcal TSS
isolate MN NJ. The putative RBS is in boldface, and putative 10 and
35 promoter sequences are underlined. An asterisk marks the predicted
amino terminus of the mature protein after removal of the signal
peptide.
|
|

View larger version (8K):
[in this window]
[in a new window]
|
FIG. 2.
Phylogenetic tree diagram of the family of SEs of
serotypes A to L. Three distinct subfamilies can be observed. Groupings
are an indication of relatedness, but distances are not quantitatively
related to evolutionary distance.
|
|

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 3.
Alignment of the mature form of SEK with representative
toxins from the major enterotoxin subfamilies (SEA representing the
SEA, -D, -E, -H, and -J subfamily; SEB representing the SEB, -C, and -G
subfamily; and SEI representing the SEI, -K, and -L subfamily).
Residues that are homologous to residues in SEK are highlighted in
black. Dashes represent gaps in the aligned sequences.
|
|
Biochemical properties of recombinant SEK.
In order to work
with the gene product, a recombinant construct was made with the
predicted N-terminal sequence, with a methionine added to the amino
terminus for expression in the pET system. This recombinant protein,
rSEK, was observed to have a pI of between 7.0 and 7.5. The pI
predicted from computer primary sequence analysis was 6.5. The
predicted molecular weight of this polypeptide was 25,539. Both of
these values were produced with the online Compute pI/MW tool
(http://expasy.cbr.nrc.ca/tools/pi_tool.html) with the
predicted mature SEK sequence. When purified and evaluated by SDS-PAGE,
the recombinant protein had an apparent molecular weight of about
30,000 (Fig. 4). It is not uncommon for
PTSAgs to have a higher apparent molecular weight by SDS-PAGE than the predicted amino acid sequence would suggest.

View larger version (96K):
[in this window]
[in a new window]
|
FIG. 4.
SDS-PAGE analysis (15% polyacrylamide gel) of rSEK. The
gel was stained with Coomassie brilliant blue R250. Lane 1, molecular
weight (MW) standards with sizes given to the left in thousands; lane
2, 10 µg of rSEK. The apparent size of rSEK was 30,000.
|
|
Detection of SEK in clinical isolates.
A set of 36 clinical
isolates was examined for the ability to produce detectable levels of
SEK. We were able to detect toxin production by Ouchterlony double
immunodiffusion in one isolate (MN JA) and were able to see a reaction
with a polyclonal antiserum on a Western blot (Fig.
5). Fourteen of the 36 isolates,
including MN NJ, contained bands of the correct size which were
reactive with the polyclonal antiserum to rSEK (data not shown).

View larger version (101K):
[in this window]
[in a new window]
|
FIG. 5.
Western immunoblot of concentrated supernatant fluid
from TSS isolate MN JA compared to purified rSEK. Samples were
electrophoresed by SDS-PAGE (15% polyacrylamide) and transferred to a
nitrocellulose membrane. The blot was developed with hyperimmune rabbit
polyclonal antiserum to rSEK. Bound antibody was detected with a
secondary antibody to rabbit immunoglobulin G conjugated to alkaline
phosphatase followed by substrate (4). Lane 1, 10 µl of
crude extract of MN JA supernatant; lane 2, 10 µg of rSEK. MW, sizes
in thousands as determined by SDS-PAGE.
|
|
Biological activity of rSEK.
The ability of rSEK to stimulate
rabbit splenocytes was assessed in a standard superantigenicity assay
(Fig. 6). We observed that rSEK was able
to stimulate splenocyte proliferation comparable to that of TSST-1. The
pyrogenic activity of rSEK and its ability to enhance host
susceptibility to endotoxin shock were also examined (Fig.
7). It was observed that rSEK caused
fever in rabbits at doses of 4.5 and 0.45 µg/kg, but not at 0.045 µg/kg. The minimum pyrogenic dose of rSEK at 4 h (defined as the
dose required to give a 0.5°C average rise in body temperature) was
0.2 µg/kg. This was consistent with minimum doses of other PTSAgs to
cause fever. The same doses that were able to cause fever enhanced the lethality of endotoxin, while the nonpyrogenic dose was not active. Finally, the lethality of rSEK when infused into rabbits from subcutaneous miniosmotic pumps was assessed. All three rabbits infused
with 200 µg of rSEK died within a 15-day period. The same dose of
TSST-1 was also lethal in this model.

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 6.
Superantigenicity assay of SEK ( ) versus TSST-1 ( )
as assessed by measuring proliferation of rabbit splenocytes (2 × 105/well/200 µl). Splenocytes in complete RPMI were
incubated for 4 days in quadruplicate samples in 96-well microtiter
plates in the presence of rSEK or TSST-1 used as a control at the
designated concentrations added in 20-µl volumes. Negative control
wells contained 20 µl of PBS rather than toxin.
[3H]thymidine (1 µCi/well) was added to all wells after
3 days, and splenocyte proliferation was measured by determining cpm of
radiolabel incorporation into DNA. Results are the average cpm of
quadruplicate wells. Values represent the mean ± standard error of the
mean.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 7.
Pyrogenicity of rSEK in rabbits and the ability of the
toxin to enhance host susceptibility to lethal endotoxin shock. rSEK
was injected intravenously at doses of 4.5, 0.45, and 0.045 µg/kg/ml
in PBS. Fever development was assessed at 0 and 4 h with rectal
thermometers. The values presented represent the mean ± standard
error of the mean. At the 4-h time point, all rabbits were injected
with 10 µg of LPS from S. enterica serovar Typhimurium.
Lethality was assessed during the first 48 h postinjection;
lethality at 4.5 and 0.45 µg/kg was significantly different from that
at 0.045 µg/kg at P = 0.05, as determined by
Fisher's exact test.
|
|
The TCR V
stimulation profile of rSEK was assessed for human T cells
from three volunteers by use of flow cytometry. Antibodies were
directed against the different TCR V
subsets in human PBMCs. It was
observed that TCR V
s 5.1, 5.2, and 6.7 were preferentially activated
by the toxin (Fig. 8). The most prominent
subset from all three subjects used was V
5.1, reaching a highest
level of 44% of the T-cell population in one case. V
5.2 and 6.7 expansions were not as strong, but were still significant (P = 0.055 and 0.045, respectively). Consistent with a superantigenic
effect, we observed an expansion of V
s in CD4+ and
CD8+ T-cell subsets. In one of the three patients tested,
TCR V
22 was also expanded, but the significance of this result was
not clear. Some T cells bearing certain TCR V
subsets were reduced in relative numbers. Examples of this effect include V
2, 3, 8, 9, and 13.1. This reduction in relative population size was not the result
of apoptosis of T cells expressing those V
s. Rather, the reduction
resulted from those T-cell populations being present in smaller numbers
through lack of stimulation relative to the T cells that were
preferentially expanded by the toxin.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 8.
TCR V profile of rSEK. Three patients' PBMCs were
stimulated with either anti-CD3 antibody (white bars), which stimulates
all T cells, or rSEK (black bars), which selectively stimulates T cells
dependent on the variable part of the chain (V ) of the TCR.
Cells were stained with monoclonal antibodies against the listed TCR
V chains (V-beta type), and the results were evaluated by flow
cytometry. The percentages of T cells expressing the listed TCR V
are shown. P values were determined by the paired Student's
t test (**, P < 0.05; *, P = 0.055). Error bars represent the standard error of the mean for
each data set.
|
|
 |
DISCUSSION |
The data presented in this work indicate that a novel enterotoxin,
designated SEK, is encoded by a gene (sek) contained on a
SaPI, designated SaPI3, that also contains the gene (seb)
for SEB. sek is also present on SaPI1 (29). SEK
shares similar biochemical and biological properties to those described
previously for enterotoxins and PTSAgs in general (5, 11).
Because the presence of multiple virulence factor genes is a defining
feature of pathogenicity islands (29), the presence of
both seb and sek on SaPI3 validates the use of
the term "pathogenicity island" in this case.
The presence of multiple expressed toxins also makes it less clear
whether any single toxin is responsible for all clinical features of
TSS induced by such clinical isolates of S. aureus. Rather,
the data suggest that these strains make multiple toxins with similar
activity and that all could contribute to human disease in the absence
of protective antibodies; this does not preclude some toxins being more
important than others due to differences in amounts made. There is a
precedent for expression of multiple toxins by TSS S. aureus
in the literature. As many as 15% of TSST-1-positive strains also
produce SEC, and 75% of TSST-1-positive strains also make SEA
(36). It now appears that certain strains may
contain even more toxin genes.
Analysis of the sequence of sek and SEK, respectively, shows
that SEK fits into a new subfamily of enterotoxins, along with the
recently described SEI (34) and SEL (unpublished data). SEK is more closely related to the SEA, -D, and -E subfamily than to
SEB and -C (Fig. 3), although sek can be genetically linked to seb, as on SaPI3. Analysis of the sequence 5' of the
putative sek translational start site reveals a
Shine-Dalgarno sequence typical of S. aureus RBSs previously
described (38). sek also contains
10 and
35
putative promoter sequences similar to those previously observed
(38).
rSEK was superantigenic, capable of stimulating proliferation of both
CD4+ and CD8+ T- cells, and pyrogenic and
enhanced the lethal effects of endotoxin in a rabbit model. It was also
lethal in a model of TSS in which miniosmotic pumps that deliver a
constant amount of toxin over a 7-day period were implanted
subcutaneously in rabbits. Although we have not evaluated rSEK for
emetic activity, its homology to the other SEs suggests that SEK does
belong to the SE subfamily of PTSAgs. It should be noted that the
protein used in these studies was cloned without its putative
N-terminal signal sequence, and in order to express the protein in the
pET system, a methionine and glycine were added to replace the
N-terminal glutamine of the recombinant protein. Thus, the N-terminal
sequence of rSEK was MGGDIGIDNLR, while the putative
N-terminal sequence of SEK was QGDIGIDNLR. This alteration
did not appear to have a significant effect on the biological activity
of the toxin, however, since rSEK exhibited comparable immunobiological
activity to those of TSST-1 and other PTSAgs (11, 51, 52).
A putative degradation product of SEK was present in the supernatant of
the clinical isolates we tested, as seen in the Western blot presented
(Fig. 5). This is also seen for other SEs, where it has been suggested that staphylococcal proteases cleave the toxins, yielding a fairly stable, lower-molecular-weight, antibody-reactive product (5, 6).
The study of SEK is likely to increase our understanding of the
structure-function relationships within the PTSAgs. The structures of
TSST-1 (1, 42), SEA to -D (46, 55), and
several streptococcal pyrogenic exotoxins (40, 45, 49)
have been solved, as well as those of a variety of mutant
staphylococcal toxins. In addition, SEB and -C have been crystallized
in complex with the TCR (13, 28), as well as TSST-1 and
SEB in complex with MHC class II (16, 17, 19). These
studies have allowed detailed models of PTSAg activation of T cells to
be developed. However, there are many facets of PTSAg activities which
have not been explained in terms of structural differences. A prime
example of this is emetic activity. The enterotoxins are uniquely
characterized by their abilities to cause emetic responses when
administered orally to monkeys (11), whereas other PTSAgs
are not emetic (11). However, we still do not completely
understand what parts of the SE molecules are required for this emetic
function. It has been proposed that the cystine loop, located in the OB
fold of the toxins, is important for emesis (15, 50), but
this has only been incompletely studied. Because SEK has only one
cysteine, the molecule does not contain a cystine loop at the usual
position. One other enterotoxin (SEI) has been identified that lacks
the cystine loop, and that protein was shown to be only weakly emetic compared to SEA, -B, and -C (34). Based on primary
structure, it is likely that SEK will act more like SEI than the other
SEs and thus be less emetic than other toxins. Structural studies of
SEs, such as SEK and -I, and comparison to structures of highly emetic
SEs may help elucidate what SE structural components are necessary for
this activity.
Structural studies of the SEK, -L, and -I subfamily of
PTSAgs may also increase our understanding of how
superantigens interact with immune cells. For example, SEK generally
functions similar to other PTSAgs in stimulation of T cells dependent
on the composition of the TCR V
, but it has a TCR V
profile
distinct from those previously observed. Only one other characterized
toxin stimulates TCR V
5.1 (SEE), and no other toxins have been
observed to stimulate V
5.2 or 6.7. The structure of the PTSAg must
dictate the TCR V
profile of the stimulated T cells (10, 16,
18). It has been seen with other toxins that a large region at
the top front (in the standard view of SEB and -C) or top back of
TSST-1 is important for TCR binding (11, 13, 22, 28).
Where SEK, SEI, and SEL interact with either TCR or MHC II remains to
be determined.
It is noteworthy that SEK has the strongest homology with other SEs in
the C-terminal
grasp domain, whereas some PTSAgs (SEA, for example)
bind to MHC class II, opposite the usual MHC II site in the OB fold
domain (46, 55). In SEA, zinc is coordinated by His187,
His225, and Asp227, which are important residues in this MHC II binding
site (46, 55). These residues are present in the same
position relative to one another in SEK (His169, His208, and Asp210),
suggesting SEK may interact with zinc and may have an MHC II binding
site in this position. The zinc binding site in SEA also requires Ser1.
Homologous residues are not present in either SEK or rSEK, implying
that some other residue would be necessary to make up the final piece
of the tetrahedral coordination site in this toxin. We do not know if
zinc is present in rSEK, but clearly the N-terminal residue normally
present on SEK (Gln1) is not required for superantigenicity, as Ser1 is
for SEA (46); rSEK, which lacks Gln1, retains
superantigenic activity.
We have shown that human PBMCs containing TCR V
5.1, 5.2, and 6.7 were significantly stimulated by rSEK in vitro. TCR V
5.1 in
particular has been observed to be overrepresented in several diseases
of unknown etiology, in particular Crohn's disease, a severe small
bowel inflammatory disorder (43). T cells from the V
5 family have also been implicated in juvenile rheumatoid arthritis and
periodontitis (32, 37). In the latter case, TCR V
6.7 has also been observed to be overrepresented (37). PTSAgs
from both S. aureus and group A streptococci have also been
implicated in forms of psoriasis and atopic dermatitis
(23-27, 53). Previous studies have isolated
S. aureus from psoriatic lesions, and some of the
organisms were categorized as non-enterotoxin producing based on
antibody testing against toxins identified at the time
(26). It is possible that new SEs, such as SEK, may play a
role in previously unexplained cases of these illnesses.
 |
ACKNOWLEDGMENTS |
This work was supported by Public Health Service research grants
AI22159, HL36577, HL37260, and AR41256. P.M.O. was supported by a
National Science Foundation fellowship and Public Health Service
training grant [AI07421].
Tim Leonard is gratefully acknowledged for help in generating figures.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, University of Minnesota Medical School, Box 196 Mayo
Bldg., 420 Delaware St. SE, Minneapolis, MN 55455. Phone: (612)
624-9471. Fax: (612) 626-0623. E-mail:
pats{at}lenti.med.umn.edu.
Editor:
J. D. Clements
 |
REFERENCES |
| 1.
|
Acharya, K. R.,
E. F. Passalacqua,
E. Y. Jones,
K. Harlos,
D. I. Stuart,
R. D. Brehm, and H. S. Tranter.
1994.
Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1.
Nature
367:94-97[CrossRef][Medline].
|
| 2.
|
Barg, N. L., and T. Harris.
1997.
Toxin-mediated syndromes, p. 527-544.
In
K. B. Crossley, and G. L. Archer (ed.), The staphylococci in human disease. Churchill Livingstone, New York, N.Y.
|
| 3.
|
Bergdoll, M. S.,
B. A. Crass,
R. F. Reiser,
R. N. Robbins, and J. P. Davis.
1981.
A new staphylococcal enterotoxin, enterotoxin F, associated with toxic shock syndrome.
Lancet
i:1017-1021.
|
| 4.
|
Blake, M. S.,
K. H. Johnston,
G. J. Russell-Jones, and E. C. Gotschlich.
1984.
A rapid, sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots.
Anal. Biochem.
136:175-179[CrossRef][Medline].
|
| 5.
|
Bohach, G. A.,
D. J. Fast,
R. D. Nelson, and P. M. Schlievert.
1990.
Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses.
Crit. Rev. Microbiol.
17:251-272[Medline].
|
| 6.
|
Bohach, G. A.,
J. P. Handley, and P. M. Schlievert.
1989.
Biological and immunological properties of the carboxyl terminus of staphylococcal enterotoxin Cl.
Infect. Immun.
57:23-28[Abstract/Free Full Text].
|
| 7.
|
Breneman, D. L.
1993.
Bacterial infection of the skin and soft tissues and their treatment.
Curr. Opin. Infect. Dis.
6:678-682.
|
| 8.
|
Choi, Y.,
J. A. Lafferty,
J. R. Clements,
J. K. Todd,
E. W. Gelfand,
J. Kappler,
P. Marrack, and B. L. Kotzin.
1990.
Selective expansion of T cells expressing V 2 in toxic shock syndrome.
J. Exp. Med.
172:981-984[Abstract/Free Full Text].
|
| 9.
|
Davis, J. P.,
P. J. Chesney,
P. J. Wand, and M. La Venture.
1980.
Toxic shock syndrome: epidemiologic features, recurrence, risk factors, and prevention.
N. Engl. J. Med.
303:1429-1435[Abstract].
|
| 10.
|
Deringer, J. R.,
R. J. Ely,
C. V. Stauffacher, and G. A. Bohach.
1996.
Subtype-specific interactions of type C staphylococcal enterotoxins with the T cell receptor.
Mol. Microbiol.
22:523-534[CrossRef][Medline].
|
| 11.
|
Dinges, M. M.,
P. M. Orwin, and P. M. Schlievert.
2000.
Exotoxins of Staphylococcus aureus.
Clin. Microbiol. Rev.
13:16-34[Abstract/Free Full Text].
|
| 12.
|
Fast, D. J.,
P. M. Schlievert, and R. D. Nelson.
1989.
Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production.
Infect. Immun.
57:291-294[Abstract/Free Full Text].
|
| 13.
|
Fields, B. A.,
E. L. Malchiodi,
H. Li,
X. Ysern,
C. V. Stauffacher,
P. M. Schlievert,
K. Karjalainen, and R. A. Mariuzza.
1996.
Crystal structure of a T-cell receptor beta-chain complexed with a superantigen.
Nature
384:188-192[CrossRef][Medline].
|
| 14.
|
Hiramatsu, K.
1995.
Molecular evolution of MRSA.
Microbiol. Immunol.
39:531-543[Medline].
|
| 15.
|
Hovde, C. J.,
J. C. Marr,
M. L. Hoffmann,
S. P. Hackett,
Y. I. Chi,
K. K. Crum,
D. L. Stevens,
C. V. Stauffacher, and G. A. Bohach.
1994.
Investigation of the role of the disulphide bond in the activity and structure of staphylococcal enterotoxin C1.
Mol. Microbiol.
13:897-909[CrossRef][Medline].
|
| 16.
|
Jardetzky, T. S.
1995.
Structural studies of the interaction of superantigens with class II major histocompatibility complex molecules, p. 67-82.
In
J. Thibodeau, and R.-P. Sekaly (ed.), Bacterial superantigens: structure, function, and therapeutic potential. R. G. Landes Co., Austin, Tex.
|
| 17.
|
Jardetzky, T. S.,
J. H. Brown,
J. C. Gorga,
L. J. Stern,
R. G. Urban,
Y. Chi,
C. V. Stauffacher,
J. L. Strominger, and D. C. Wiley.
1994.
Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.
Nature
368:711-718[CrossRef][Medline].
|
| 18.
|
Kappler, J.,
B. Kotzin,
L. Herron,
E. W. Gelfand,
R. D. Bigler,
A. Boylston,
S. Carrel,
D. N. Posnett,
Y. Choi, and P. Marrack.
1989.
V -specific stimulation of human T cells by staphylococcal toxins.
Science
244:811-813[Abstract/Free Full Text].
|
| 19.
|
Kim, J.,
R. G. Urban,
J. L. Strominger, and D. C. Wiley.
1994.
Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1.
Science
266:1870-1874[Abstract/Free Full Text].
|
| 20.
|
Kornblum, J.,
B. N. Kreiswirth,
S. J. Projan,
H. Ross, and R. P. Novick.
1990.
Agr: a polycistronic locus regulating exoprotein synthesis in Staphylococcus aureus, p. 373-402.
In
R. P. Novick (ed.), Molecular biology of the staphylococci. VCH Publishers, Inc., New York, N.Y.
|
| 21.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 22.
|
Leder, L.,
A. Llera,
P. M. Lavoie,
M. I. Lebedeva,
H. Li,
R. Sekaly,
G. A. Bohach,
P. J. Gahr,
P. M. Schlievert,
K. Karjalainen, and R. A. Mariuzza.
1998.
A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor chain and major histocompatibility complex class II.
J. Exp. Med.
187:823-833[Abstract/Free Full Text].
|
| 23.
|
Leung, D. Y. M.,
M. Gately,
A. Trumble,
B. Ferguson-Darnell,
P. M. Schlievert, and L. J. Picker.
1995.
Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interlenkin 12 production.
J. Exp. Med.
181:747-753[Abstract/Free Full Text].
|
| 24.
|
Leung, D. Y. M.,
H. C. Meissner,
D. R. Fulton,
D. L. Murray,
B. L. Kotzin, and P. M. Schlievert.
1993.
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome.
Lancet
342:1385-1388[CrossRef][Medline].
|
| 25.
|
Leung, D. Y. M.,
J. B. Travers,
R. Giorno,
D. A. Norris,
R. Skinner,
J. Aelion,
L. V. Kazemi,
M. H. Kim,
A. E. Trumble,
M. Kotb, and P. M. Schlievert.
1995.
Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis.
J. Clin. Investig.
96:2106-2112.
|
| 26.
|
Leung, D. Y. M.,
P. Walsh,
R. Giorno, and D. A. Norris.
1993.
A potential role for superantigens in the pathogenesis of psoriasis.
J. Investig Dermatol.
100:225-228[CrossRef][Medline].
|
| 27.
|
Lewis, H. M.,
B. S. Baker,
S. Bokth,
A. V. Powles,
J. J. Garioch,
H. Valdimarsson, and L. Fry.
1993.
Restricted T-cell receptor V usage in the skin of patients with guttate and chronic plaque psoriasis.
Br. J. Dermatol.
129:514-520[CrossRef][Medline].
|
| 28.
|
Li, H.,
A. Llera,
D. Tsuchiya,
L. Leder,
X. Ysern,
P. M. Schlievert,
K. Karjalainen, and R. A. Mariuzza.
1998.
Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B.
Immunity
9:807-816[CrossRef][Medline].
|
| 29.
|
Lindsay, J. A.,
A. Ruzin,
H. F. Ross,
N. Kurepina, and R. P. Novick.
1998.
The gene for toxic shock toxin is carried by a family of mobile pathogenicity islands in Staphylococcus aureus.
Mol. Microbiol.
29:527-543[CrossRef][Medline].
|
| 30.
|
Marrack, P., and J. Kappler.
1990.
The staphylococcal enterotoxins and their relatives.
Science
248:705-711[Abstract/Free Full Text].
|
| 31.
|
Marrack, P., and J. Kappler.
1994.
Subversion of the immune system by pathogens.
Cell
76:323-332[CrossRef][Medline].
|
| 32.
|
McDermott, M.,
D. L. Kastner,
J. D. Holloman,
G. Schmidt-Wolf,
A. S. Lundberg,
A. A. Sinha,
C. Hsu,
P. Cashin,
M. G. Molloy, and B. Mulcahy.
1995.
The role of T-cell receptor beta chain genes in susceptibility to rheumatoid arthritis.
Arthritis Rheum.
38:91-95[Medline].
|
| 33.
|
Miethke, T.,
C. Wahl,
K. Heeg, and H. Wagner.
1995.
The pathophysiology of bacterial superantigens in vivo, p. 161-179.
In
J. Thibodeau, and R.-P. Sekaly (ed.), Bacterial superantigens: structure, function and therapeutic potential. R. G. Landes Co., Austin, Tex.
|
| 34.
|
Munson, S. H.,
M. T. Tremaine,
M. J. Betley, and R. A. Welch.
1998.
Identification and characterization of staphylococcal enterotoxin types G and I from Staphylococcus aureus.
Infect. Immun.
66:3337-3348[Abstract/Free Full Text].
|
| 35.
|
Murray, D. L.,
D. H. Ohlendorf, and P. M. Schlievert.
1995.
Staphylococcal and streptococcal superantigens: their role in human diseases.
ASM News
61:229-235.
|
| 36.
|
Musser, J. M.,
P. M. Schlievert,
A. W. Chow,
P. Ewan,
B. N. Kreiswirth,
V. T. Rosdahl,
A. S. Naidu,
W. Witte, and R. K. Selander.
1990.
A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome.
Proc. Natl. Acad. Sci. USA
87:225-229[Abstract/Free Full Text].
|
| 37.
|
Nakajima, T.,
K. Yamazaki, and K. Hara.
1996.
Biased T-cell receptor V gene usage in tissues with periodontal disease.
J. Periodontal Res.
31:2-10[CrossRef][Medline].
|
| 38.
|
Novick, R. P.
1990.
The staphylococcus as a molecular genetic system, p. 1-40.
In
R. P. Novick (ed.), Molecular biology of the staphylococci. VCH, New York, N.Y.
|
| 39.
|
Ouchterlony, O.
1962.
Diffusion-in-gel methods for immunological analysis.
Prog. Allergy
6:30[Medline].
|
| 40.
|
Papageorgiou, A. C.,
C. M. Collins,
D. M. Gutman,
J. B. Kline,
S. M. O'Brien,
H. S. Tranter, and K. R. Acharya.
1999.
Structural basis for the recognition of superantigen streptococcal pyrogenic exotoxin A (SpeA1) by MHC class II molecules and T-cell receptors.
EMBO J.
18:9-21[CrossRef][Medline].
|
| 41.
|
Parsonnet, J.,
Z. A. Gillis,
A. G. Richter, and G. B. Pier.
1987.
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1.
Infect. Immun.
55:1070-1076[Abstract/Free Full Text].
|
| 42.
|
Prasad, G. S.,
C. A. Earhart,
D. L. Murray,
R. P. Novick,
P. M. Schlievert, and D. H. Ohlendorf.
1993.
Structure of toxic shock syndrome toxin 1.
Biochemistry
32:13761-13766[CrossRef][Medline].
|
| 43.
|
Prindiville, T. P.,
M. C. Cantrell,
T. Matsumoto,
W. R. Brown,
A. A. Ansari,
B. L. Kotzin, and M. E. Gershwin.
1996.
Analysis of function, specificity and T-cell receptor expression of cloned mucosal T-cell lines in Crohn's disease.
J. Autoimmun.
9:193-204[CrossRef][Medline].
|
| 44.
|
Rago, J. V.,
G. M. Vath,
G. A. Bohach,
D. H. Ohlendorf, and P. M. Schlievert.
2000.
Mutational analysis of the superantigen staphylococcal exfoliative toxin A (ETA).
J. Immunol.
164:2207-2213[Abstract/Free Full Text].
|
| 45.
|
Roussel, A.,
B. F. Anderson,
H. M. Baker,
J. D. Fraser, and E. N. Baker.
1997.
Crystal structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules.
Nat. Struct. Biol.
4:645-653.
|
| 46.
|
Schad, E. M.,
I. Zaitseva,
V. N. Zaitsev,
M. Dohlsten,
T. Kalland,
P. M. Schlievert,
D. H. Ohlendorf, and L. A. Svensson.
1995.
Crystal structure of the superantigen staphylococcal exotoxin type A.
EMBO J.
14:3292-3301[Medline].
|
| 47.
|
Schlievert, P. M.
1982.
Enhancement of host susceptibility to lethal endotoxin shock by staphylococcal pyrogenic exotoxin type C.
Infect. Immun.
36:123-128[Abstract/Free Full Text].
|
| 48.
|
Schlievert, P. M.
1986.
Staphylococcal enterotoxin B and toxic shock syndrome toxin-1 are significantly associated with nonmenstrual TSS.
Lancet
i:1149.
|
| 49.
|
Schlievert, P. M.,
G. A. Bohach,
D. H. Ohlendorf,
C. V. Stauffacher,
D. Y. M. Leung,
G. S. Prasad,
C. A. Earhart,
L. M. Jablonski,
M. L. Hoffmann, and Y. I. Chi.
1995.
Molecular structure of staphylococcus and streptococcus superantigens.
J. Clin. Immunol.
15:4-10.
|
| 50.
|
Schlievert, P. M.,
L. M. Jablonski,
M. Roggiani,
I. Sadler,
S. Callantine,
D. T. Mitchell,
D. H. Ohlendorf, and G. A. Bohach.
2000.
Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals.
Infect. Immun.
68:3630-3634[Abstract/Free Full Text].
|
| 51.
|
Schlievert, P. M.,
K. N. Shands,
B. B. Dan,
G. P. Schmid, and R. D. Nishimura.
1981.
Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic shock syndrome.
J. Infect. Dis.
143:509-516[Medline].
|
| 52.
|
Schlevert, P. M., and D. W. Watson.
1978.
Group A streptococcal pyrogenic exotoxin: pyrogenicity, alteration of blood-brain barrier, and separation of sites for pyrogenicity and enhancement of lethal endotoxin shock.
Infect. Immun.
21:753-763[Abstract/Free Full Text].
|
| 53.
|
Strickland, I. H. P.,
P. J. Hauk,
A. E. Trumble,
L. J. Picker, and D. Y. M. Leung.
1999.
Evidence for superantigen involvement in skin homing of T-cells in atopic dermatitis.
J. Investig. Dermatol.
112:249-253[CrossRef][Medline].
|
| 54.
|
Sugiyama, H., and T. Hayama.
1965.
Abdominal viscera as site of emetic action for staphylococcal enterotoxin in the monkey.
J. Infect. Dis.
115:330-336[Medline].
|
| 55.
|
Svensson, L. A.,
E. M. Schad,
M. Sundstrom,
P. Antonsson,
T. Kalland, and M. Dohlsten.
1997.
Staphylococcal enterotoxins A, D and E, p. 199-230.
In
D. Y. M. Leung, B. T. Huber, and P. M. Schlievert (ed.), Superantigens: molecular biology, immunology, and relevance to human disease. Marcel Dekker, Inc., New York, N.Y.
|
| 56.
|
Todd, J.,
M. Fishaut,
F. Kapral, and T. Welch.
1978.
Toxic shock syndrome associated with phage group-I staphylococci.
Lancet.
ii:1116-1118.
|
Infection and Immunity, January 2001, p. 360-366, Vol. 69, No. 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.1.360-366.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Takano, T., Higuchi, W., Otsuka, T., Baranovich, T., Enany, S., Saito, K., Isobe, H., Dohmae, S., Ozaki, K., Takano, M., Iwao, Y., Shibuya, M., Okubo, T., Yabe, S., Shi, D., Reva, I., Teng, L.-J., Yamamoto, T.
(2008). Novel Characteristics of Community-Acquired Methicillin-Resistant Staphylococcus aureus Strains Belonging to Multilocus Sequence Type 59 in Taiwan. Antimicrob. Agents Chemother.
52: 837-845
[Abstract]
[Full Text]
-
Yamamoto, T., Dohmae, S., Saito, K., Otsuka, T., Takano, T., Chiba, M., Fujikawa, K., Tanaka, M.
(2006). Molecular Characteristics and In Vitro Susceptibility to Antimicrobial Agents, Including the Des-Fluoro(6) Quinolone DX-619, of Panton-Valentine Leucocidin-Positive Methicillin-Resistant Staphylococcus aureus Isolates from the Community and Hospitals. Antimicrob. Agents Chemother.
50: 4077-4086
[Abstract]
[Full Text]
-
Blaiotta, G., Fusco, V., von Eiff, C., Villani, F., Becker, K.
(2006). Biotyping of Enterotoxigenic Staphylococcus aureus by Enterotoxin Gene Cluster (egc) Polymorphism and spa Typing Analyses. Appl. Environ. Microbiol.
72: 6117-6123
[Abstract]
[Full Text]
-
Nakayama, A., Okayama, A., Hashida, M., Yamamoto, Y., Takebe, H., Ohnaka, T., Tanaka, T., Imai, S.
(2006). Development of a routine laboratory direct detection system of staphylococcal enterotoxin genes.. J Med Microbiol
55: 273-277
[Abstract]
[Full Text]
-
Jorgensen, H. J., Mork, T., Caugant, D. A., Kearns, A., Rorvik, L. M.
(2005). Genetic Variation among Staphylococcus aureus Strains from Norwegian Bulk Milk. Appl. Environ. Microbiol.
71: 8352-8361
[Abstract]
[Full Text]
-
Jorgensen, H. J., Mork, T., Rorvik, L. M.
(2005). The Occurrence of Staphylococcus aureus on a Farm with Small-Scale Production of Raw Milk Cheese. J DAIRY SCI
88: 3810-3817
[Abstract]
[Full Text]
-
Takizawa, Y., Taneike, I., Nakagawa, S., Oishi, T., Nitahara, Y., Iwakura, N., Ozaki, K., Takano, M., Nakayama, T., Yamamoto, T.
(2005). A Panton-Valentine Leucocidin (PVL)-Positive Community-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Strain, Another Such Strain Carrying a Multiple-Drug Resistance Plasmid, and Other More-Typical PVL-Negative MRSA Strains Found in Japan. J. Clin. Microbiol.
43: 3356-3363
[Abstract]
[Full Text]
-
Ikeda, T., Tamate, N., Yamaguchi, K., Makino, S.-i.
(2005). Mass Outbreak of Food Poisoning Disease Caused by Small Amounts of Staphylococcal Enterotoxins A and H. Appl. Environ. Microbiol.
71: 2793-2795
[Abstract]
[Full Text]
-
Smyth, D. S, Hartigan, P. J, Meaney, W. J, Fitzgerald, J R., Deobald, C. F, Bohach, G. A, Smyth, C. J
(2005). Superantigen genes encoded by the egc cluster and SaPIbov are predominant among Staphylococcus aureus isolates from cows, goats, sheep, rabbits and poultry. J Med Microbiol
54: 401-411
[Abstract]
[Full Text]
-
Smith-Palmer, A., Stewart, J., Fyfe, L.
(2004). Influence of subinhibitory concentrations of plant essential oils on the production of enterotoxins A and B and {alpha}-toxin by Staphylococcus aureus. J Med Microbiol
53: 1023-1027
[Abstract]
[Full Text]
-
Lovseth, A., Loncarevic, S., Berdal, K. G.
(2004). Modified Multiplex PCR Method for Detection of Pyrogenic Exotoxin Genes in Staphylococcal Isolates. J. Clin. Microbiol.
42: 3869-3872
[Abstract]
[Full Text]
-
Al-Shangiti, A. M., Naylor, C. E., Nair, S. P., Briggs, D. C., Henderson, B., Chain, B. M.
(2004). Structural Relationships and Cellular Tropism of Staphylococcal Superantigen-Like Proteins. Infect. Immun.
72: 4261-4270
[Abstract]
[Full Text]
-
Omoe, K., Imanishi, K., Hu, D.-L., Kato, H., Takahashi-Omoe, H., Nakane, A., Uchiyama, T., Shinagawa, K.
(2004). Biological Properties of Staphylococcal Enterotoxin-Like Toxin Type R. Infect. Immun.
72: 3664-3667
[Abstract]
[Full Text]
-
Omoe, K., Hu, D.-L., Takahashi-Omoe, H., Nakane, A., Shinagawa, K.
(2003). Identification and Characterization of a New Staphylococcal Enterotoxin-Related Putative Toxin Encoded by Two Kinds of Plasmids. Infect. Immun.
71: 6088-6094
[Abstract]
[Full Text]
-
Orwin, P. M., Fitzgerald, J. R., Leung, D. Y. M., Gutierrez, J. A., Bohach, G. A., Schlievert, P. M.
(2003). Characterization of Staphylococcus aureus Enterotoxin L. Infect. Immun.
71: 2916-2919
[Abstract]
[Full Text]
-
Becker, K., Friedrich, A. W., Lubritz, G., Weilert, M., Peters, G., von Eiff, C.
(2003). Prevalence of Genes Encoding Pyrogenic Toxin Superantigens and Exfoliative Toxins among Strains of Staphylococcus aureus Isolated from Blood and Nasal Specimens. J. Clin. Microbiol.
41: 1434-1439
[Abstract]
[Full Text]
-
Hu, D.-L., Omoe, K., Shimoda, Y., Nakane, A., Shinagawa, K.
(2003). Induction of Emetic Response to Staphylococcal Enterotoxins in the House Musk Shrew (Suncus murinus). Infect. Immun.
71: 567-570
[Abstract]
[Full Text]
-
Vojtov, N., Ross, H. F., Novick, R. P.
(2002). Global repression of exotoxin synthesis by staphylococcal superantigens. Proc. Natl. Acad. Sci. USA
99: 10102-10107
[Abstract]
[Full Text]
-
Yarwood, J. M., McCormick, J. K., Paustian, M. L., Orwin, P. M., Kapur, V., Schlievert, P. M.
(2002). Characterization and Expression Analysis of Staphylococcus aureus Pathogenicity Island 3. IMPLICATIONS FOR THE EVOLUTION OF STAPHYLOCOCCAL PATHOGENICITY ISLANDS. J. Biol. Chem.
277: 13138-13147
[Abstract]
[Full Text]
-
Omoe, K., Ishikawa, M., Shimoda, Y., Hu, D.-L., Ueda, S., Shinagawa, K.
(2002). Detection of seg, seh, and sei genes in Staphylococcus aureus Isolates and Determination of the Enterotoxin Productivities of S. aureus Isolates Harboring seg, seh, or sei Genes. J. Clin. Microbiol.
40: 857-862
[Abstract]
[Full Text]
-
Gravet, A., Couppie, P., Meunier, O., Clyti, E., Moreau, B., Pradinaud, R., Monteil, H., Prevost, G.
(2001). Staphylococcus aureus Isolated in Cases of Impetigo Produces Both Epidermolysin A or B and LukE-LukD in 78% of 131 Retrospective and Prospective Cases. J. Clin. Microbiol.
39: 4349-4356
[Abstract]
[Full Text]
-
Lee, S.-U., Ferens, W., Davis, W. C., Hamilton, M. J., Park, Y.-H., Fox, L. K., Naessens, J., Bohach, G. A.
(2001). Identity of Activation Molecule 3 on Superantigen-Stimulated Bovine Cells Is CD26. Infect. Immun.
69: 7190-7193
[Abstract]
[Full Text]
-
(2001). Correction. J. Immunol.
166: 4260-4260
[Full Text]